
    
      This will be a 2-year, randomized, open-label, prospective, parallel-group study. It only be
      held in China-Japan Friendship Hospital. Subjects with Carotid Atherosclerosis Plaques who
      meet all inclusion and none of the exclusion criteria will be randomized in a 1:1 ratio to
      receive treatment of rosuvastatin (5 mg, 10mg, 20mg) dosing adjustment by LDL-c level or
      fixed dose 5 mg. The study will consist of two phases: the Screening/Baseline period（-1to
      week 0）and the Follow-up period(0 to month 24). The follow-up period will comprise seven
      visits.
    
  